Potent and Selective Inhibitors of Human Reticulocyte 12/15-Lipoxygenase as Anti-Stroke Therapies

[Image: see text] A key challenge facing drug discovery today is variability of the drug target between species, such as with 12/15-lipoxygenase (12/15-LOX), which contributes to ischemic brain injury, but its human and rodent isozymes have different inhibitor specificities. In the current work, we...

Descripción completa

Detalles Bibliográficos
Autores principales: Rai, Ganesha, Joshi, Netra, Jung, Joo Eun, Liu, Yu, Schultz, Lena, Yasgar, Adam, Perry, Steve, Diaz, Giovanni, Zhang, Qiangli, Kenyon, Victor, Jadhav, Ajit, Simeonov, Anton, Lo, Eng H., van Leyen, Klaus, Maloney, David J., Holman, Theodore R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Chemical Society 2014
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4033661/
https://www.ncbi.nlm.nih.gov/pubmed/24684213
http://dx.doi.org/10.1021/jm401915r

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4033661/
https://www.ncbi.nlm.nih.gov/pubmed/24684213
http://dx.doi.org/10.1021/jm401915r

Ejemplares similares